
AstraZeneca to retire MedImmune brand amid restructuring
pharmafile | February 15, 2019 | News story | Medical Communications | AstraZeneca, Business, MedImmune, R&D, biologics, restructuring
AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D units.
The announcement comes just a month after AstraZeneca announced organisational changes which will see the creation of therapy area specific R&D units.
AstraZeneca acquired MedImmune in 2007, running the firm as a separate biologics unit. However the restructuring will see the company integrated into AstraZeneca’s new R&D units.
The changes will not affect MedImmune’s ongoing partnerships and collaborations. AstraZeneca did not offer insight as to whether the restructuring would result in changes to management; however a spokesperson suggested that no layoffs are expected.
The news comes after a number of high profile resignations. Nevertheless recent figures show that AstraZeneca’s fourth quarter revenue jumped 11% year on year, reaching $6.4 billion
“As we recently entered a new phase in our strategic development, we have refined our organisation to position ourselves for the next phase of our journey,” CEO Pascal Soriot said.
Louis Goss
Related Content

Recipharm designates Germany site as Centre of Excellence
The multi-product facility recently underwent significant renovations

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …






